Back to top Open menu arrow
Download Reprints
Sections
METHODS RESULTS DISCUSSION Article Information Clinical Points
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

Original Research August 26, 2024

Safe Ketamine Use and Pregnancy: A Nationwide Survey and Retrospective Review of Informed Consent, Counseling, and Testing Practices

J Clin Psychiatry 2024;85(3):24m15293

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

Abstract

Objective: Ketamine is contraindicated in pregnancy given the lack of knowledge about potential effects on a developing fetus. This study aimed to characterize current clinical practices specific to pregnancy and reproduction related to the use of ketamine for the treatment of psychiatric illness.

Methods: Online surveys were sent to outpatient ketamine clinics across the United States inquiring about practices related to pregnancy. Responses were collected between September and November 2023. Additionally, a retrospective medical record review was conducted to ascertain the frequency of pregnancy testing and contraception use with ketamine treatments administered at a large academic health system. Online, publicly available informed consent documents were also reviewed for language related to pregnancy.

Results: Fewer than half of survey respondents (n = 126) discuss specific risks related to pregnancy and fetal ketamine exposure during the informed consent process. Twenty percent of clinics require pregnancy tests prior to treatment, and 10.5% require subsequent testing during treatment; however, 22.9% of clinics do not have a standard process for testing. Only 13.7% of clinics specifically recommend or require use of contraception. Retrospective record review revealed that all patients who received intravenous ketamine for psychiatric indications in an academic medical center were pregnancy tested weekly, but only half were using contraception during treatment.

Conclusion: Many women with the potential to become pregnant are treated with ketamine for psychiatric illness. Results of the present study reveal that risks of fetal ketamine exposure are often overlooked, indicating a need for increased awareness about reproductive concerns when prescribing ketamine for the treatment of psychiatric disorders.

J Clin Psychiatry 2024;85(3):24m15293

Author affiliations are listed at the end of this article.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Alnefeesi Y, Chen-Li D, Krane E, et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022;151:693–709. PubMed CrossRef
  2. Johnston JN, Kadriu B, Kraus C, et al. Ketamine in neuropsychiatric disorders: an update. Neuropsychopharmacology. 2024;49(1):23–40. PubMed
  3. Peskin E, Gudin J, Schatman ME. Increased demand for ketamine infusions and associated complexities. J Pain Res. 2023;16:295–299. PubMed CrossRef
  4. Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399–405. PubMed CrossRef
  5. McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383–399. PubMed CrossRef
  6. Swainson J, McGirr A, Blier P, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the use of racemic ketamine in adults with major depressive disorder: recommandations du groupe de travail du réseau canadien pour les traitements de L’humeur et de L’anxiété (canmat) concernant L’utilisation de La kétamine racémique chez les adultes souffrant de trouble dépressif majeur. Can J Psychiatry. 2021;66(2):113–125. PubMed
  7. Zaki N, Chen L, Lane R, et al. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacol. 2023;48:1225–1233.
  8. Kritzer MD, Pae CU, Masand PS. Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability. Expert Opin Drug Saf. 2022;21(6):725–732. PubMed CrossRef
  9. Esketamine (Spravato). Janssen Pharmaceuticals; 2019.Refstyled
  10. Ketamine (Ketalar). Hospira, Inc; 2022.
  11. Ellingson A, Haram K, Sagen N, et al. Transplacental passage of ketamine after intravenous administration. Acta Anaesthesiol Scand. 1977;21(1):41–44. PubMed CrossRef
  12. Cohen ML, Chan SL, Way WL, et al. Distribution in the brain and metabolism of ketamine in the rat after intravenous administration. Anesthesiology. 1973;39(4):370–376. PubMed CrossRef
  13. Cheung HM, Yew DTW. Effects of perinatal exposure to ketamine on the developing brain. Front Neurosci. 2019;13:138. PubMed
  14. Zhao T, Li Y, Wei W, et al. Ketamine administered to pregnant rats in the second trimester causes long-lasting behavioral disorders in offspring. Neurobiol Dis. 2014;68:145–155. PubMed CrossRef
  15. Coronel-Oliveros CM, Pacheco-Calderón R. Prenatal exposure to ketamine in rats: implications on animal models of schizophrenia. Dev Psychobiol. 2018;60(1):30–42. PubMed CrossRef
  16. Jeevakumar V, Driskill C, Paine A, et al. Ketamine administration during the second postnatal week induces enduring schizophrenia-like behavioral symptoms and reduces parvalbumin expression in the medial prefrontal cortex of adult mice. Behav Brain Res. 2015;282:165–175. PubMed CrossRef
  17. Brambrink AM, Evers AS, Avidan MS, et al. Ketamine-induced neuroapoptosis in the fetal and neonatal rhesus macaque brain. Anesthesiology. 2012;116(2):372–384. PubMed CrossRef
  18. Paule MG, Li M, Allen RR, et al. Ketamine anesthesia during the first week of life can cause long-lasting cognitive deficits in rhesus monkeys. Neurotoxicol Teratol. 2011;33(2):220–230. PubMed CrossRef
  19. Su PH, Chang YZ, Chen JY. Infant with in utero ketamine exposure: quantitative measurement of residual dosage in hair. Pediatr Neonatol. 2010;51(5):279–284. PubMed CrossRef
  20. Lodge D, Mercier MS. Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol. 2015;172(17):4254–4276. PubMed CrossRef
  21. Wachsman L, Schuetz S, Chan LS, et al. What happens to babies exposed to phencyclidine (PCP) in utero? Am J Drug Alcohol Abuse. 1989;15(1):31–39. PubMed CrossRef
  22. Strauss AA, Modaniou HD, Bosu SK. Neonatal manifestations of maternal phencyclidine (PCP) abuse. Pediatrics. 1981;68(4):550–552. PubMed
  23. Unintended Pregnancy in the United States. Guttmacher Institute; 2011.
  24. Standards of Practice in the Therapeutic Use of Subanesthetic Ketamine. American Society of Ketamine Physicians, Psychotherapists and Practitioners; 2020. Accessed January 22, 2024. https://www.askp.org/askp3-standards/
  25. Parikh SV, Lopez D, Vande Voort JL, et al. Developing an IV ketamine clinic for treatment-resistant depression: a primer. Psychopharmacol Bull. 2021;51(3):109–124. PubMed
  26. Mathai DS, Lee SM, Mora V, et al. Mapping consent practices for outpatient psychiatric use of ketamine. J Affect Disord. 2022;312:113–121. PubMed CrossRef
  27. United States Population Growth by Region. United States Census Bureau; 2022.
  28. Burton KW. Time for a National Ketamine Registry, Experts Say. Medscape; 2023. Accessed January 22, 2024. https://www.medscape.com/viewarticle/988310?form=fpf#vp_1
  29. Nillni YI, Wesselink AK, Gradus JL, et al. Depression, anxiety, and psychotropic medication use and fecundability. Am J Obstet Gynecol. 2016;215(4):453.e1–453.e8. PubMed CrossRef
  30. Statement on the Risks Associated with Use of Valproic Acid (Sodium Valproate) in Women and Girls of Childbearing Potential. World Health Organization; 2023. Accessed January 27, 2024. https://www.who.int/news/item/02-05-2023-useof-valproic-acid-in-women-and-girls-of-childbearing-potential.
  31. Medicines With Teratogenic Potential: What is Effective Contraception and How Often is Pregnancy Testing Needed? Medicines and Healthcare Products Regulatory Agency Drug Safety Update; 2019. Accessed January 22, 2024. https://assets.publishing.service.gov.uk/media/5c937af4ed915d07a4a46547/March-2019-PDF-final.pdf.
  32. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397–404. PubMed CrossRef
  33. Marchesi C. Is perinatal psychiatry a needed specialty? J Clin Psychiatry. 2015;76(9):1251. PubMed CrossRef
  34. The National Pregnancy Registry for Psychiatric Medications. Massachusetts General Hospital Center for Women’s Mental Health. Accessed January 27, 2024. https://womensmentalhealth.org/research/pregnancyregistry/
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite